Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

NCT03747484 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Terminated due to insufficient funding

Conditions

Other Skin

Interventions

BIOLOGICAL: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR
DRUG: Avelumab
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Interferon Gamma-1b

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]
[object Object]